P=N/A, N=591, Active, not recruiting, Medtronic Vascular | Trial completion date: Apr 2026 --> Aug 2026

Sixty female Sprague-Dawley rats were randomly assigned to six groups: control (sham exposure), autophagy inhibition (3-methyladenine, 3-MA), autophagy activation (rapamycin, RAP), +Gz exposure, +Gz exposure with autophagy inhibition, and +Gz exposure with autophagy activation...Excessive autophagy exacerbates ferroptosis via ferritinophagy-mediated iron release, whereas autophagy inhibition is protective against intestinal damage by preserving the Nrf2-GPX4 axis function. Targeting autophagy and ferroptosis may provide new therapeutic strategies for mitigating high-G-induced gastrointestinal injury in aerospace medicine.

Furthermore, we identify a synergistic antitumor effect between KPT-330 and translation inhibitors, including everolimus and homoharringtonine. Notably, the disruptive impact of KPT-330 on CRC homeostasis extends to other cancer cell lineages, underscoring its broad mechanistic relevance. Collectively, our findings elucidate a novel mechanism through which KPT-330 destabilizes CRC via translational dysregulation and highlight its potential therapeutic utility in combination regimens for DDLPS.

P4, N=150, Completed, Chong Kun Dang Pharmaceutical | Recruiting --> Completed

Western blot analysis demonstrated inhibition of EGFR/PI3K/AKT/mTOR (mechanistic Target of Rapamycin) and STAT3/HSP90 signaling, along with marked downregulation of PI3K and phosphorylation levels of EGFR, AKT, and STAT3...These findings suggest that CDY exerts multi-targeted anti-cancer effects by modulating oncogenic signaling pathways and epigenetic regulators, supporting its potential as a promising bioactive lead for prostate cancer. Collectively, these findings demonstrate that CDY exerts mechanistically coordinated anticancer effects in vitro and in chorioallantoic membrane (CAM) models, warranting further validation in mammalian in vivo systems to assess translational relevance.

P1/2, N=9, Recruiting, Astellas Gene Therapies

Based on the suspected enhancing mass identified at the one-month postoperative CT follow-up and the confirmed malignant potential, the patient has been advised to initiate adjuvant mTOR inhibitor therapy (Everolimus)...In young patients with TSC and atypical renal masses, malignant PEComa should be considered in the differential diagnosis. Multidisciplinary evaluation, genetic testing, and awareness of emerging mTOR-targeted therapies are essential for optimal management.

Tumor cells are highly dependent on branched-chain amino acids, which can activate mechanistic target of rapamycin complex 1, but the downstream catabolite branched-chain α-keto acids (BCKAs) are not well studied in this context...Mutation of the BCKA-binding site in Notch2 abolishes this effect in vivo. Together, these findings identify BCKAs as signaling metabolites that mediate tumor immunosuppression through direct sensing by Notch2.

P3, N=65, Terminated, University Hospital, Rouen | Completed --> Terminated; Difficulty in enrolling new patients

Its function was investigated through small interfering RNA-mediated silencing, lentiviral overexpression, pamidronate treatment, in vitro proliferation, migration, invasion, and apoptosis assays, xenograft models, phosphoproteomic profiling, and Western blot validation. FDPS knockdown was further associated with decreased B-cell lymphoma 2 expression, reduced phosphorylation of Caspase-9 at Ser196, increased cleaved Caspase-3, and reduced phosphorylation of mechanistic target of rapamycin at Ser2448. Collectively, these findings suggest that FDPS contributes to HCC progression and may serve as a candidate biomarker and therapeutic target.

P1/2, N=54, Recruiting, Celcuity Inc | Trial completion date: Nov 2027 --> Jan 2030 | Trial primary completion date: Nov 2025 --> Jan 2028

Microsurgical resection of SEGA is a safe and effective therapeutic option, particularly in patients without hydrocephalus. Early surgical intervention may reduce the need for VPS and long-term complications, offering a valid alternative or complement to mechanistic target of rapamycin inhibitor therapy, with durable tumor control especially in unilateral cases.